tiprankstipranks
Trending News
More News >
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market

Innate Pharma (IPHA) Financial Statements

Compare
129 Followers

Innate Pharma Financial Overview

Innate Pharma's market cap is currently $168.56M. The company's EPS TTM is $-0.296; its P/E ratio is -2.96; Innate Pharma is scheduled to report earnings on September 17, 2025, and the estimated EPS forecast is $-0.14. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue€ 12.62M€ 51.90M€ 57.67M€ 12.11M€ 69.77M
Gross Profit€ 12.62M€ 5.62M€ 6.01M€ -22.30M€ 20.07M
Operating Income€ -51.58M€ -12.67M€ -57.42M€ -47.83M€ 1.08M
EBITDA€ -46.91M€ -1.84M€ -12.28M€ -43.23M€ 13.30M
Net Income€ -49.47M€ -7.57M€ -58.10M€ -52.81M€ -63.98M
Balance Sheet
Cash & Short-Term Investments€ 80.77M€ 92.46M€ 101.48M€ 119.84M€ 151.64M
Total Assets€ 111.06M€ 175.19M€ 207.86M€ 267.50M€ 307.42M
Total Debt€ 31.00M€ 39.89M€ 42.25M€ 44.25M€ 19.09M
Net Debt€ -35.40M€ -30.71M€ -41.97M€ -59.51M€ -117.70M
Total Liabilities€ 102.22M€ 132.29M€ 153.71M€ 160.06M€ 151.45M
Stockholders' Equity€ 8.83M€ 51.90M€ 54.15M€ 107.44M€ 155.97M
Cash Flow
Free Cash Flow€ -7.29M€ -34.91M€ -20.28M€ -59.79M€ -63.09M
Operating Cash Flow€ -6.90M€ -32.56M€ -19.15M€ -58.46M€ -51.81M
Investing Cash Flow€ 9.20M€ 20.63M€ 1.88M€ -917.00K€ -13.37M
Financing Cash Flow€ -6.01M€ -1.97M€ -1.83M€ 26.82M€ -1.14M
Currency in EUR

Innate Pharma Earnings and Revenue History

Innate Pharma Debt to Assets

Innate Pharma Cash Flow

Innate Pharma Forecast EPS vs Actual EPS